Summary of findings for the effects of antituberculosis treatment compared with no antituberculosis treatment in infertile women with genital tuberculosis without structural damage
| Population | Infertile women with genital tuberculosis without structural damage (only PCR positive) | |||||
| Intervention | Antituberculosis treatment (orally isoniazid, rifampicin, pyrazinamide and ethambutol (HRZE) for 6 months) | |||||
| Comparator | No antituberculosis treatment | |||||
| Outcomes | No of participants (studies) | Antituberculosis treatment | No antituberculosis treatment | Relative effect (95% CI) | Absolute effects | Certainty of the evidence (GRADE) |
| Pregnancy follow-up: 12 months | 100 (1 RCT) | 25/50 (50%) | 21/50 (42%) | RR: 1.17 (0.79 to 1.74) | 71 more per 1000 (from 88 fewer to 311 more) | ⊕ΟΟΟ *,† Very low |
| Full-term pregnancy follow-up: 12 months | 100 (1 RCT) | 21/50 (42%) | 19/50 (38%) | RR: 1.09 (0.73 to 1.61) | 34 more per 1000 (from 103 fewer to 232 more) | ⊕ΟΟΟ *,† Very low |
| Abortion or intrauterine death follow-up: 12 months | 100 (1 RCT) | 3/50 (6%) | 1/50 (2%) | RR: 1.53 (0.84 to 2.80) | 11 more per 1000 (from 3 fewer to 36 more) | ⊕ΟΟΟ *,† Very low |
| Ectopic pregnancy follow-up: 12 months | 100 (1 RCT) | 1/50 (2%) | 0/50 (0%) | Not estimable | Not estimable | ⊕ΟΟΟ *,† Very low |
| Adverse events follow-up: 12 months | The study reported no adverse events in either group. | |||||
*We downgraded one level of evidence due to serious risk of bias: No blinding of participants and staff, and no blinding of outcome assessors.
†We downgraded two levels of evidence due to very serious imprecision.
GRADE, Grading of Recommendations, Assessment, Development and Evaluations; RCT, randomised controlled trial; RR, risk ratio.